Mentioned in ?
References in periodicals archive ?
* Breakthrough Seizures: Recurrence of status epilepticus during the treatment although it was controlled initially, resulting in the need for a change of therapy.
11% of total NCC cases had breakthrough seizures. The seizure recurrence in patients treated with albendazole in a study done by Gogia et al.
The most common reasons for breakthrough seizures reported by the patients were sleep deprivation, stress, alcohol, non-compliance and menses.
The combination of alcohol consumption, sleep deprivation (as alcohol consumption is often associated with evening social events), and missed medication can lower seizure threshold and place the adolescent at risk for breakthrough seizures.
Seizure safety in either of these populations is paramount; however, those children who undergo surgical evaluation due to persistent breakthrough seizures on anti-epileptic medication are already at an increased risk for seizures, which only increases further upon admission to the hospital given their rapid medication taper.
The pharmacy benefits manager's analysis stems from questions over the last several years about generic AED drugs, specifically whether there is a higher risk of so-called breakthrough seizures or toxic side effects after patients are switched from a brand-name antiepileptic to a generic version.
I have had repeated personal experience with well-controlled epilepsy patients having breakthrough seizures when they switched from Dilantin to generic phenytoin, and there are published reports of a less anecdotal nature with similar findings.